SCHEMBL9914396

SCHEMBL9914396

CCOC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N(CCCCCBr)[C@@H]1c1ccc(C#N)cc1

nearest known ligand 0.76

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ELANE P08246 20/20 0.76
CYP2C9 P11712 3/20 0.63
CYP3A4 P08684 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13872773 1.00 ELANE (0.76) ELANECYP2C9CYP3A4
SCHEMBL13872763 1.00 ELANE (0.76) ELANECYP2C9CYP3A4
SCHEMBL9914381 0.97 ELANE (0.79) ELANECYP2C9CYP3A4
SCHEMBL13872771 0.97 ELANE (0.79) ELANECYP2C9CYP3A4
SCHEMBL8260420 0.96 ELANE (0.82) ELANECYP2C9CYP3A4
SCHEMBL8259476 0.96 ELANE (0.82) ELANECYP2C9CYP3A4
SCHEMBL8261232 0.96 ELANE (0.82) ELANECYP2C9CYP3A4
SCHEMBL13872807 0.92 ELANE (0.78) ELANECYP2C9CYP3A4
SCHEMBL16326278 0.92 ELANE (0.81) ELANECYP2C9CYP3A4
SCHEMBL8257430 0.92 ELANE (0.73) ELANECYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957082-B2 Tetrahydropyrrolopyrimidinediones and their use in therapy CHIESI FARMACEUTICI S.P.A (IT) 2015-02-17 US disclosed
US-8957082-B2 Tetrahydropyrrolopyrimidinediones and their use in therapy CHIESI FARMACEUTICI S.P.A (IT) 2015-02-17 US disclosed
US-20120202826-A1 Tetrahydropyrrolopyrimidinediones And Their Use In Therapy CHIESI FARMACEUTICI S.P.A. (IT) 2012-08-09 US disclosed
US-20120202826-A1 Tetrahydropyrrolopyrimidinediones And Their Use In Therapy CHIESI FARMACEUTICI S.P.A. (IT) 2012-08-09 US disclosed
US-8198288-B2 Tetrahydropyrrolopyrimidinediones and their use in therapy PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2012-06-12 US disclosed
US-8198288-B2 Tetrahydropyrrolopyrimidinediones and their use in therapy PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2012-06-12 US disclosed
US-20090111795-A1 Multimers of Heterocyclic Compounds and Their Use ARGENTA DISCOVERY LIMITED (GB) 2009-04-30 US disclosed
US-20090111795-A1 Multimers of Heterocyclic Compounds and Their Use ARGENTA DISCOVERY LIMITED (GB) 2009-04-30 US disclosed
US-20090093477-A1 TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY CHIESI FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
US-20090093477-A1 TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY CHIESI FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202826-A1 Tetrahydropyrrolopyrimidinediones And Their Use In Therapy SERPINB1, ELANE, MPO ELANE 2/4885CYP2C9 1646/4885CYP3A4 712/4885
US-20090093477-A1 TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY NOX1, NOX3, ELANE ELANE 3/4885CYP2C9 2216/4885CYP3A4 1050/4885
US-20090111795-A1 Multimers of Heterocyclic Compounds and Their Use MRM1, ME2, SDHA ELANE 293/4885CYP2C9 461/4885CYP3A4 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.